Current Report Filing (8-k)
May 26 2022 - 8:13AM
Edgar (US Regulatory)
0001633070
false
0001633070
2022-05-26
2022-05-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 26, 2022
AXCELLA
HEALTH INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-38901 |
|
26-3321056 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
840
Memorial Drive
Cambridge,
Massachusetts |
02139 |
(Address
of principal executive offices) |
(Zip Code) |
Registrant's telephone number, including area
code: (857) 320-2200
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
¨ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of
each class |
|
Trading Symbol(s) |
|
Name of each
exchange on which
registered |
Common
Stock, $0.001 Par Value |
|
AXLA |
|
Nasdaq Global Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
On May 26, 2022, Axcella Health Inc. (the “Company”
or “Axcella”) issued a press release announcing that it has completed patient enrollment for its Phase 2a clinical trial
of AXA1125 for the treatment of Long COVID and that it is suspending its Phase 2 clinical trial of AXA1665 for the reduction in risk of
Overt Hepatic Encephalopathy (OHE) recurrence while exploring partnerships and alternate indications for AXA1665.
A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated into this Item 8.01 by reference.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AXCELLA HEALTH INC. |
|
|
Date: May 26, 2022 |
By: |
/s/ William R. Hinshaw, Jr. |
|
|
William R. Hinshaw, Jr. |
|
|
Chief Executive Officer, President and Director |
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Apr 2023 to Apr 2024